This novel OX40L/CD40L-armed adenovirus coated with human melanoma antigen A3 (MAGE-A3(161−180)) and human cancer-testis antigen (NY-ESO-1(91−110)), designated “PeptiCRAd-1,” will be tested in combination with anti-PD-1 ICI in a phase I clinical trial in patients with triple-negative breast cancer (TNBC), melanoma, non-small cell lung cancer, and sarcoma. Here, MAGEA3 is linked to sarcoma.